Shots:
- Nurix has entered a global collaboration with Roche to develop & commercialize bexobrutideg (PO), a BTK targeted protein degrader, which is under P-II/III trial for chronic lymphocytic leukemia
- Nurix will receive $700M upfront & ~$2.3B in milestones. Development costs will be shared (40% Nurix & 60% Roche), with both co-commercializing the drug & equally sharing profits & losses in the US; Roche will lead ex-US commercialization, while Nurix will receive royalties ranging from the low to high-teens
- Beyond ongoing P-II/III trials, the collaboration plans multiple studies in hematologic malignancies & P-II trials in immune-mediated diseases, incl. multiple sclerosis & chronic spontaneous urticaria
Ref: Globenewswire | Image: Nurix & Roche | Press Release
Related News: Nurix Therapeutics Presents New Data from P-I of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL at ASH’25
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
